Mylan N.V. and Upjohn Inc. - proposed merger

Acquirer(s)

  • Mylan N.V.

Target(s)

  • Upjohn Inc.

Summary

The proposed combination of Mylan N.V. (Mylan) and Pfizer's Upjohn Inc. division (Upjohn), which will be renamed Viatris at the closing of the transaction (the proposed transaction).
 
Mylan and Upjohn both supply cardiovascular, neurology & pain, psychiatry, urology and ophthalmology pharmaceutical products in Australia.

Market definition

The ACCC will publish a Public Competition Assessment in due course.

Competition analysis

The ACCC will publish a Public Competition Assessment in due course.

Timeline

DateEvent
24/03/2020ACCC commenced review under the Merger Process Guidelines.
22/04/2020Closing date for submissions. The ACCC will place an indicative decision date here shortly.
04/06/2020ACCC awaiting further information from the parties. Former provisional date for announcement of ACCC's finding (11 June 2020) is delayed. ACCC will announce a proposed decision date in due course.
19/08/2020ACCC commenced market consultation on proposed s87B undertaking. ACCC timeline recommenced.
31/08/2020Closing date for submissions relating to the draft proposed divestment undertaking.
10/09/2020ACCC announced it would not oppose the proposed acquisition, subject to section 87B undertakings accepted by the ACCC.